Corpus
PascalFrancis
Racine
Corpus
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Geographical Difference in Parkinson's Disease Prevalence Within West Scotland

Identifieur interne : 000F68 ( PascalFrancis/Corpus ); précédent : 000F67; suivant : 000F69

Geographical Difference in Parkinson's Disease Prevalence Within West Scotland

Auteurs : Edward J. Newman ; Katherine A. Grosset ; Donald G. Grosset

Source :

RBID : Pascal:09-0136788

Descripteurs français

English descriptors

Abstract

The wide range in reported prevalence of Parkinson's disease (PD) in the United Kingdom (between 108 and 164 per 100,000) is usually attributed to differences in study methodology. We report prevalence of PD in four geographic areas within West Scotland, which was calculated using the same methodology, from prescription database searches within primary care, combined with full case record review. Crude prevalence was 119.2 per 100,000 (95% CI 109.7-128.6) and age-adjusted prevalence was 129.5 (95% CI 119.6-139.4) in 92 General Practices covering a population of 511,927. Prevalence was significantly lower in South Glasgow (men 98.3, CI 78.7-117.9; women 83.9, CI 65.6-102.2) than South Lanarkshire (men 202.7, CI 175.0-230.4; women 151.1, CI 127.7-174.5), age-adjusted rates, both P < 0.001. Factors associated with higher prevalence of PD, such as lower cigarette smoking rates, higher education level, and rural living, were higher in South Lanarkshire than South Glasgow, but the magnitude of the difference was greater than expected considering studies describing relative risk for these factors. Access to services, and specialist clinic attendance were both higher for South Glasgow, which may influence diagnostic accuracy, time to diagnosis, and time to initiating antiparkinson therapy. Exploration of these factors is justified to explain further such wide variation in PD prevalence.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 0885-3185
A03   1    @0 Mov. disord.
A05       @2 24
A06       @2 3
A08 01  1  ENG  @1 Geographical Difference in Parkinson's Disease Prevalence Within West Scotland
A11 01  1    @1 NEWMAN (Edward J.)
A11 02  1    @1 GROSSET (Katherine A.)
A11 03  1    @1 GROSSET (Donald G.)
A14 01      @1 University of Glasgow, Department of Neurology, Institute of Neurological Sciences, Southern General Hospital @2 Glasgow @3 GBR @Z 1 aut. @Z 2 aut. @Z 3 aut.
A20       @1 401-406
A21       @1 2009
A23 01      @0 ENG
A43 01      @1 INIST @2 20953 @5 354000186999840120
A44       @0 0000 @1 © 2009 INIST-CNRS. All rights reserved.
A45       @0 24 ref.
A47 01  1    @0 09-0136788
A60       @1 P
A61       @0 A
A64 01  1    @0 Movement disorders
A66 01      @0 USA
C01 01    ENG  @0 The wide range in reported prevalence of Parkinson's disease (PD) in the United Kingdom (between 108 and 164 per 100,000) is usually attributed to differences in study methodology. We report prevalence of PD in four geographic areas within West Scotland, which was calculated using the same methodology, from prescription database searches within primary care, combined with full case record review. Crude prevalence was 119.2 per 100,000 (95% CI 109.7-128.6) and age-adjusted prevalence was 129.5 (95% CI 119.6-139.4) in 92 General Practices covering a population of 511,927. Prevalence was significantly lower in South Glasgow (men 98.3, CI 78.7-117.9; women 83.9, CI 65.6-102.2) than South Lanarkshire (men 202.7, CI 175.0-230.4; women 151.1, CI 127.7-174.5), age-adjusted rates, both P < 0.001. Factors associated with higher prevalence of PD, such as lower cigarette smoking rates, higher education level, and rural living, were higher in South Lanarkshire than South Glasgow, but the magnitude of the difference was greater than expected considering studies describing relative risk for these factors. Access to services, and specialist clinic attendance were both higher for South Glasgow, which may influence diagnostic accuracy, time to diagnosis, and time to initiating antiparkinson therapy. Exploration of these factors is justified to explain further such wide variation in PD prevalence.
C02 01  X    @0 002B17
C02 02  X    @0 002B17G
C03 01  X  FRE  @0 Maladie de Parkinson @2 NM @5 01
C03 01  X  ENG  @0 Parkinson disease @2 NM @5 01
C03 01  X  SPA  @0 Parkinson enfermedad @2 NM @5 01
C03 02  X  FRE  @0 Pathologie du système nerveux @5 02
C03 02  X  ENG  @0 Nervous system diseases @5 02
C03 02  X  SPA  @0 Sistema nervioso patología @5 02
C03 03  X  FRE  @0 Prévalence @5 09
C03 03  X  ENG  @0 Prevalence @5 09
C03 03  X  SPA  @0 Prevalencia @5 09
C03 04  X  FRE  @0 Ouest @5 10
C03 04  X  ENG  @0 West @5 10
C03 04  X  SPA  @0 Oeste @5 10
C03 05  X  FRE  @0 Ecosse @2 NG @5 11
C03 05  X  ENG  @0 Scotland @2 NG @5 11
C03 05  X  SPA  @0 Escocia @2 NG @5 11
C03 06  X  FRE  @0 Epidémiologie @5 12
C03 06  X  ENG  @0 Epidemiology @5 12
C03 06  X  SPA  @0 Epidemiología @5 12
C03 07  X  FRE  @0 Base de données @5 13
C03 07  X  ENG  @0 Database @5 13
C03 07  X  SPA  @0 Base dato @5 13
C07 01  X  FRE  @0 Grande Bretagne @2 NG
C07 01  X  ENG  @0 Great Britain @2 NG
C07 01  X  SPA  @0 Gran Bretaña @2 NG
C07 02  X  FRE  @0 Royaume-Uni @2 NG
C07 02  X  ENG  @0 United Kingdom @2 NG
C07 02  X  SPA  @0 Reino Unido @2 NG
C07 03  X  FRE  @0 Europe @2 NG
C07 03  X  ENG  @0 Europe @2 NG
C07 03  X  SPA  @0 Europa @2 NG
C07 04  X  FRE  @0 Pathologie de l'encéphale @5 37
C07 04  X  ENG  @0 Cerebral disorder @5 37
C07 04  X  SPA  @0 Encéfalo patología @5 37
C07 05  X  FRE  @0 Syndrome extrapyramidal @5 38
C07 05  X  ENG  @0 Extrapyramidal syndrome @5 38
C07 05  X  SPA  @0 Extrapiramidal síndrome @5 38
C07 06  X  FRE  @0 Maladie dégénérative @5 39
C07 06  X  ENG  @0 Degenerative disease @5 39
C07 06  X  SPA  @0 Enfermedad degenerativa @5 39
C07 07  X  FRE  @0 Pathologie du système nerveux central @5 40
C07 07  X  ENG  @0 Central nervous system disease @5 40
C07 07  X  SPA  @0 Sistema nervosio central patología @5 40
N21       @1 096
N44 01      @1 OTO
N82       @1 OTO

Format Inist (serveur)

NO : PASCAL 09-0136788 INIST
ET : Geographical Difference in Parkinson's Disease Prevalence Within West Scotland
AU : NEWMAN (Edward J.); GROSSET (Katherine A.); GROSSET (Donald G.)
AF : University of Glasgow, Department of Neurology, Institute of Neurological Sciences, Southern General Hospital/Glasgow/Royaume-Uni (1 aut., 2 aut., 3 aut.)
DT : Publication en série; Niveau analytique
SO : Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 3; Pp. 401-406; Bibl. 24 ref.
LA : Anglais
EA : The wide range in reported prevalence of Parkinson's disease (PD) in the United Kingdom (between 108 and 164 per 100,000) is usually attributed to differences in study methodology. We report prevalence of PD in four geographic areas within West Scotland, which was calculated using the same methodology, from prescription database searches within primary care, combined with full case record review. Crude prevalence was 119.2 per 100,000 (95% CI 109.7-128.6) and age-adjusted prevalence was 129.5 (95% CI 119.6-139.4) in 92 General Practices covering a population of 511,927. Prevalence was significantly lower in South Glasgow (men 98.3, CI 78.7-117.9; women 83.9, CI 65.6-102.2) than South Lanarkshire (men 202.7, CI 175.0-230.4; women 151.1, CI 127.7-174.5), age-adjusted rates, both P < 0.001. Factors associated with higher prevalence of PD, such as lower cigarette smoking rates, higher education level, and rural living, were higher in South Lanarkshire than South Glasgow, but the magnitude of the difference was greater than expected considering studies describing relative risk for these factors. Access to services, and specialist clinic attendance were both higher for South Glasgow, which may influence diagnostic accuracy, time to diagnosis, and time to initiating antiparkinson therapy. Exploration of these factors is justified to explain further such wide variation in PD prevalence.
CC : 002B17; 002B17G
FD : Maladie de Parkinson; Pathologie du système nerveux; Prévalence; Ouest; Ecosse; Epidémiologie; Base de données
FG : Grande Bretagne; Royaume-Uni; Europe; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED : Parkinson disease; Nervous system diseases; Prevalence; West; Scotland; Epidemiology; Database
EG : Great Britain; United Kingdom; Europe; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD : Parkinson enfermedad; Sistema nervioso patología; Prevalencia; Oeste; Escocia; Epidemiología; Base dato
LO : INIST-20953.354000186999840120
ID : 09-0136788

Links to Exploration step

Pascal:09-0136788

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Geographical Difference in Parkinson's Disease Prevalence Within West Scotland</title>
<author>
<name sortKey="Newman, Edward J" sort="Newman, Edward J" uniqKey="Newman E" first="Edward J." last="Newman">Edward J. Newman</name>
<affiliation>
<inist:fA14 i1="01">
<s1>University of Glasgow, Department of Neurology, Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Grosset, Katherine A" sort="Grosset, Katherine A" uniqKey="Grosset K" first="Katherine A." last="Grosset">Katherine A. Grosset</name>
<affiliation>
<inist:fA14 i1="01">
<s1>University of Glasgow, Department of Neurology, Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Grosset, Donald G" sort="Grosset, Donald G" uniqKey="Grosset D" first="Donald G." last="Grosset">Donald G. Grosset</name>
<affiliation>
<inist:fA14 i1="01">
<s1>University of Glasgow, Department of Neurology, Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">09-0136788</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0136788 INIST</idno>
<idno type="RBID">Pascal:09-0136788</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F68</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Geographical Difference in Parkinson's Disease Prevalence Within West Scotland</title>
<author>
<name sortKey="Newman, Edward J" sort="Newman, Edward J" uniqKey="Newman E" first="Edward J." last="Newman">Edward J. Newman</name>
<affiliation>
<inist:fA14 i1="01">
<s1>University of Glasgow, Department of Neurology, Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Grosset, Katherine A" sort="Grosset, Katherine A" uniqKey="Grosset K" first="Katherine A." last="Grosset">Katherine A. Grosset</name>
<affiliation>
<inist:fA14 i1="01">
<s1>University of Glasgow, Department of Neurology, Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Grosset, Donald G" sort="Grosset, Donald G" uniqKey="Grosset D" first="Donald G." last="Grosset">Donald G. Grosset</name>
<affiliation>
<inist:fA14 i1="01">
<s1>University of Glasgow, Department of Neurology, Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Database</term>
<term>Epidemiology</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Prevalence</term>
<term>Scotland</term>
<term>West</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Prévalence</term>
<term>Ouest</term>
<term>Ecosse</term>
<term>Epidémiologie</term>
<term>Base de données</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The wide range in reported prevalence of Parkinson's disease (PD) in the United Kingdom (between 108 and 164 per 100,000) is usually attributed to differences in study methodology. We report prevalence of PD in four geographic areas within West Scotland, which was calculated using the same methodology, from prescription database searches within primary care, combined with full case record review. Crude prevalence was 119.2 per 100,000 (95% CI 109.7-128.6) and age-adjusted prevalence was 129.5 (95% CI 119.6-139.4) in 92 General Practices covering a population of 511,927. Prevalence was significantly lower in South Glasgow (men 98.3, CI 78.7-117.9; women 83.9, CI 65.6-102.2) than South Lanarkshire (men 202.7, CI 175.0-230.4; women 151.1, CI 127.7-174.5), age-adjusted rates, both P < 0.001. Factors associated with higher prevalence of PD, such as lower cigarette smoking rates, higher education level, and rural living, were higher in South Lanarkshire than South Glasgow, but the magnitude of the difference was greater than expected considering studies describing relative risk for these factors. Access to services, and specialist clinic attendance were both higher for South Glasgow, which may influence diagnostic accuracy, time to diagnosis, and time to initiating antiparkinson therapy. Exploration of these factors is justified to explain further such wide variation in PD prevalence.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0885-3185</s0>
</fA01>
<fA03 i2="1">
<s0>Mov. disord.</s0>
</fA03>
<fA05>
<s2>24</s2>
</fA05>
<fA06>
<s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Geographical Difference in Parkinson's Disease Prevalence Within West Scotland</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>NEWMAN (Edward J.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>GROSSET (Katherine A.)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>GROSSET (Donald G.)</s1>
</fA11>
<fA14 i1="01">
<s1>University of Glasgow, Department of Neurology, Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA20>
<s1>401-406</s1>
</fA20>
<fA21>
<s1>2009</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>20953</s2>
<s5>354000186999840120</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>24 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>09-0136788</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Movement disorders</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>The wide range in reported prevalence of Parkinson's disease (PD) in the United Kingdom (between 108 and 164 per 100,000) is usually attributed to differences in study methodology. We report prevalence of PD in four geographic areas within West Scotland, which was calculated using the same methodology, from prescription database searches within primary care, combined with full case record review. Crude prevalence was 119.2 per 100,000 (95% CI 109.7-128.6) and age-adjusted prevalence was 129.5 (95% CI 119.6-139.4) in 92 General Practices covering a population of 511,927. Prevalence was significantly lower in South Glasgow (men 98.3, CI 78.7-117.9; women 83.9, CI 65.6-102.2) than South Lanarkshire (men 202.7, CI 175.0-230.4; women 151.1, CI 127.7-174.5), age-adjusted rates, both P < 0.001. Factors associated with higher prevalence of PD, such as lower cigarette smoking rates, higher education level, and rural living, were higher in South Lanarkshire than South Glasgow, but the magnitude of the difference was greater than expected considering studies describing relative risk for these factors. Access to services, and specialist clinic attendance were both higher for South Glasgow, which may influence diagnostic accuracy, time to diagnosis, and time to initiating antiparkinson therapy. Exploration of these factors is justified to explain further such wide variation in PD prevalence.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Pathologie du système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Prévalence</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Prevalence</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Prevalencia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Ouest</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>West</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Oeste</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Ecosse</s0>
<s2>NG</s2>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Scotland</s0>
<s2>NG</s2>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Escocia</s0>
<s2>NG</s2>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Epidémiologie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Epidemiology</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Epidemiología</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Base de données</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Database</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Base dato</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Grande Bretagne</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Great Britain</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Gran Bretaña</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Royaume-Uni</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>United Kingdom</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Reino Unido</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Europe</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Europe</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Europa</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Pathologie du système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21>
<s1>096</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
<server>
<NO>PASCAL 09-0136788 INIST</NO>
<ET>Geographical Difference in Parkinson's Disease Prevalence Within West Scotland</ET>
<AU>NEWMAN (Edward J.); GROSSET (Katherine A.); GROSSET (Donald G.)</AU>
<AF>University of Glasgow, Department of Neurology, Institute of Neurological Sciences, Southern General Hospital/Glasgow/Royaume-Uni (1 aut., 2 aut., 3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 3; Pp. 401-406; Bibl. 24 ref.</SO>
<LA>Anglais</LA>
<EA>The wide range in reported prevalence of Parkinson's disease (PD) in the United Kingdom (between 108 and 164 per 100,000) is usually attributed to differences in study methodology. We report prevalence of PD in four geographic areas within West Scotland, which was calculated using the same methodology, from prescription database searches within primary care, combined with full case record review. Crude prevalence was 119.2 per 100,000 (95% CI 109.7-128.6) and age-adjusted prevalence was 129.5 (95% CI 119.6-139.4) in 92 General Practices covering a population of 511,927. Prevalence was significantly lower in South Glasgow (men 98.3, CI 78.7-117.9; women 83.9, CI 65.6-102.2) than South Lanarkshire (men 202.7, CI 175.0-230.4; women 151.1, CI 127.7-174.5), age-adjusted rates, both P < 0.001. Factors associated with higher prevalence of PD, such as lower cigarette smoking rates, higher education level, and rural living, were higher in South Lanarkshire than South Glasgow, but the magnitude of the difference was greater than expected considering studies describing relative risk for these factors. Access to services, and specialist clinic attendance were both higher for South Glasgow, which may influence diagnostic accuracy, time to diagnosis, and time to initiating antiparkinson therapy. Exploration of these factors is justified to explain further such wide variation in PD prevalence.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du système nerveux; Prévalence; Ouest; Ecosse; Epidémiologie; Base de données</FD>
<FG>Grande Bretagne; Royaume-Uni; Europe; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Prevalence; West; Scotland; Epidemiology; Database</ED>
<EG>Great Britain; United Kingdom; Europe; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Prevalencia; Oeste; Escocia; Epidemiología; Base dato</SD>
<LO>INIST-20953.354000186999840120</LO>
<ID>09-0136788</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F68 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000F68 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0136788
   |texte=   Geographical Difference in Parkinson's Disease Prevalence Within West Scotland
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024